Nattokinase is a potent fibrinolytic enzyme extracted from Natto. The objective of this study
was to compare the efficacy of the natto extract taken by healthy volunteers, dialysis
patients, and patients with cardiovascularrisk factors on the fibrinolytic factors and blood
lipids. The study has two primary objectives: to evaluate the effect of oral intake of
nattokinase in normal subjects, patients under dialysis, and patients of cardiovascular high
risk group, and to compare the effect of oral intake of nattokinase among three groups.
Fifteen subjects, 20-70 years, for each group will be enrolled to take the capsules of natto
extract orally for 2 months. Fibrinolytic factors, vital signs and blood lipids for efficacy,
and body weight, renal function and self-administered questionnaire for safety will be
assessed at screening, 3, 7, 28, and 56 days after the initiation of intake, and 2 weeks
after the cease of intake.